CD20 Antibody (OTI4B4)

CD20 is a non-glycosylated phosphoprotein that is expressed on the surface of normal and malignant B cells and functions in mediating calcium transport and B cell differentiation (1,2). CD20 is encoded by the membrane-spanning 4-domain family A member 1 (MS4A1) gene and, in humans, is located on chromosome 11q12 (1). The CD20 protein is 297 amino acids (aa) in length with a theoretical molecular weight (MW) of 33 kDa (1,2). Structurally, the CD20 protein has four membrane-spanning domains, two extracellular loop domains, and intracellular N- and C-terminal domains (1,2). CD20 is expressed at specific stages of B cell maturation including pre-B cells, mature naive and activated B cells, and memory B cells, but is absent from plasmablasts and plasma cells (1,3,4). Expression of CD20 is often increased on malignant B cells associated with various B cell disorders such as chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and rheumatoid arthritis (2-4). Anti-CD20 monoclonal antibody (mAb)-based therapies have become an appealing target for treating these immune-related disorders and cancers (1-5). Rituximab, a chimeric mAb, was the first FDA approved CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma that is now commonly used to treat MS (2,3). Since its initial approval in 1997, several other chimeric and humanized anti-CD20 mAbs have been developed including Ofatumumab, Ublituximab, and Obinutuzumab (1-5). B cell depletion via CD20 mAbs can occur under different mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis (1-4). Many ongoing studies are focused on combination therapies with CD20 mAbs as an addition to chemotherapy, B cell receptor (BCR) signaling inhibitors, or BH3 mimetics (1,2,4). Additionally, the effects of bispecific antibodies and CD20 chimeric antigen receptor (CAR) T cell therapies are under investigation for the treatment of B cell malignancies (4,5).

References

1. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506. https://doi.org/10.3324/haematol.2019.243543

2. Payandeh Z, Bahrami AA, Hoseinpoor R, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019; 109:2415-2426. https://doi.org/10.1016/j.biopha.2018.11.121

3. Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022; 269(3):1316-1334. https://doi.org/10.1007/s00415-021-10744-x

4. Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021; 21(2):161-181. https://doi.org/10.1080/14712598.2020.1822318

5. Sharman JP. Targeting CD20: teaching an old dog new tricks. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):273-278. https://doi.org/10.1182/hematology.2019000031

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 3 confirmed species: Mouse, Rat, Goat.

We have publications tested in 1 application: IHC-P.

Showing Publications 1 - 4 of 4.

Publications using NBP2-45454	Applications	Species
Balzano T, Del Rey NL, Esteban-García N et Al. Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates NPJ Parkinsons Dis 2024-06-17 [PMID: 38886348]
El-Naseery NI, Elewa YHA, El-Behery EI, Dessouky AA Human umbilical cord blood-derived mesenchymal stem cells restored hematopoiesis by improving radiation induced bone marrow niche remodeling in rats Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft 2023-07-15 [PMID: 37460043] (IHC-P, Rat) Details: 1:1000 dilution	IHC-P	Rat
Tsugami Y, Nakayama S, Suzuki N et al. Investigating mammary glands of lactating goats for the presence of tertiary lymphoid organs Frontiers in immunology 2022-08-10 [PMID: 36032165] (IHC-P, Goat) Details: Mammary gland tissue from Tokara and Shiba Goats	IHC-P	Goat
Benvenuto M, Ciuffa S, Focaccetti C et al. Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells Scientific reports 2021-09-24 [PMID: 34561494] (IHC-P, Mouse)	IHC-P	Mouse

Images	Ratings	Applications	Species	Date	Details
Enlarge	4 reviewed by: Verified Customer	WB	Human	08/27/2017	View Summary Application Western Blot Sample Tested B cell lymphoma Species Human Lot W001
Enlarge	5 reviewed by: Verified Customer	ICC	Canine	06/28/2017	View Summary Application Immunocytochemistry Sample Tested Dog whole blood Species Canine Lot W001

Array NBP2-45454

• CD20 Antibodies
• CD20 Antibody Pair
• CD20 ELISA Kits
• CD20 Lysates
• CD20 Proteins